CD34 and acute myeloid leukemia: Here, we demonstrated, in a fourth PDX model followed for 7 months after AML injection, that TCRFLT3D/Y cells in vitro can specifically and efficiently target and kill leukemia-propagating CD34+ FLT3D835Y-mutated AML cells.